The Next Frontier in the fight against atherosclerosis: immune therapiesNew Strategies injection cardiovascular disease in patients with vaccine and monoclonal antibodies to combat atherosclerosis could soon change the landscape treatment of heart disease buy evista . Both approaches, Professor Jan Nilsson told delegates at the Frontiers in Cardiovascular Biology 2012 meeting can be really ground breaking, because for the first time they target the underlying cause of CVD. FCVB the Council meeting was organized on Basic Cardiovascular Science the European Society of Cardiology , held at the South Kensington Campus of Imperial College in London. At high risk for at high risk for MI probably the first candidate for the immune system approaches such treatments because they mechanisms of action mechanisms of action may be used in addition to current therapies, ‘said Nilsson, who is Professor of Experimental Cardiovascular Research at the University of Lund, Sweden, and a key player in the development of the immune system treatments. Undoubtedly, meeting ‘atherosclerosis and the immune system: extension of inflammation,’said Nilsson, with the Phase 2a studies of recombinant antibodies currently in the U.S. And Canada, and the expected results announced Quarter IV, 2012, such treatments might soon a clinical reality. ‘If all goes well could be the first in the class of these treatments within four to five years to be licensed,’he added.
, further along the development path, and already in clinical trials is an entirely different immune approach, the injection of antibodies targeted to oxidized LDL. The rationale is that since oxidized LDL plays a major role in the development of atherosclerotic plaques and harmful inflammatory processes , which should be directly oxidized LDL reduce inflammation of plaque and reduce inflammation, says Nilsson. More »